Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. (Q33419897)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. |
scientific article |
Statements
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors (English)
Michelle T Ashworth
Jonathan Strosberg
Jonathan W Goldman
David Mendelson
Gregory Springett
Alan P Venook
Sabine Loechner
Lee S Rosen
David Parry
Stuart Shumway
Jennifer A Grabowsky
Tomoko Freshwater
Christopher Sorge
Soonmo Peter Kang
Randi Isaacs
Pamela N Munster
20 January 2015